Work

A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma

Year: 2010

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-010-9516-1

Authors: Dale R. Shepard, Matthew M. Cooney, Paul Elson, Ronald M. Bukowski, Robert Dreicer, Brian I. Rini, Jorge A. Garcia

Institutions: Cleveland Clinic, University Hospitals of Cleveland

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1989252557

FWCI: 0.984

Cites: 15

Cited by: 20

Related to: 10